Cargando…

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer

BACKGROUND: Survivin and monoamine oxidase A (MAOA) levels are elevated in prostate cancer (PCa) compared to normal prostate glands. However, the relationship between survivin and MAOA in PCa is unclear. METHODS: We examined MAOA expression in the prostate lobes of a conditional PTEN-deficient mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, S, Adisetiyo, H, Tamura, S, Grande, F, Garofalo, A, Roy-Burman, P, Neamati, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506394/ https://www.ncbi.nlm.nih.gov/pubmed/26103574 http://dx.doi.org/10.1038/bjc.2015.228

Ejemplares similares

Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2016)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential
por: Khan, S, et al.
Publicado: (2009)

Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma
por: Adisetiyo, Helty, et al.
Publicado: (2013)

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells
por: Saito, T, et al.
Publicado: (2008)

Characterisation of the anti-apoptotic function of survivin-ΔEx3 during TNFα−mediated cell death
por: Malcles, M-H, et al.
Publicado: (2007)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling
por: Deevi, R, et al.
Publicado: (2011)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
por: Khandelwal, A, et al.
Publicado: (2008)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2011)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
por: Kashiwagi, Eiji, et al.
Publicado: (2018)

Profilin-1 is a negative regulator of mammary carcinoma aggressiveness
por: Zou, L, et al.
Publicado: (2007)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
por: Delord, J-P, et al.
Publicado: (2010)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
por: Lecis, D, et al.
Publicado: (2010)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model
por: Kususda, Y, et al.
Publicado: (2012)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis
por: Pal, Deeksha, et al.
Publicado: (2017)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer
por: Collins, L, et al.
Publicado: (2006)

Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer
por: Sacca, P, et al.
Publicado: (2007)

Human fucosyltransferase 6 enables prostate cancer metastasis to bone
por: Li, J, et al.
Publicado: (2013)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tf25o0ts85d1vvl22f6p1bmuc6